Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Inclusion Criteria: * Histologically and/or cytologically confirmed endometrioid, serous, clear cell, carcinosarcoma, or de-differentiated or undifferentiated endometrial cancer with radiographic and/or clinical evidence of disease progression * Documented microsatellite stable disease as tested by either microsatellite instability polymerase chain reaction (MSI PCR) or deoxyribonucleic acid (DNA) mismatch repair (MMR) by immunohistochemistry (IHC) * Self-identify as being of predominantly (\>50%) Black race, inclusive of Black, African-American, Black Hispanic (Afro-Latinx), African, or Afro-Caribbean ancestry * Received, ineligible for (by investigator determination), or declined platinum containing chemotherapy * Received no greater than two prior lines of therapy. Maintenance therapies and hormonal therapies will NOT count as a line of therapy. * Measurable disease as determined by RECIST v1.1: * At least one lesion of ≥10 mm in the longest diameter for a non-lymph node, or ≥15 mm in the short-axis diameter for a lymph node that is serially measurable using computerized tomography/magnetic resonance imaging (CT/MRI) * Target lesions limited to a radiated field must show evidence of substantial size increase according to previous scans to be deemed a target lesion * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Ability to swallow oral medications * Patients who are not postmenopausal or have not undergone hysterectomy must have a documented nega…